Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia
Simone E. Dekker, Delphine Réa, Jean‐Michel Cayuela, Isabell Arnhardt, Jessica Leonard, Michael Heuser
Abstract
In this review, we discuss the use of measurable residual disease (MRD) in AML, ALL, and chronic myeloid leukemia (CML). Our aims were to review the different methodologies for MRD assessment; describe the clinical relevance and medical decision making on the basis of MRD; compare and contrast the usage of MRD across AML, ALL, and CML; and discuss what patients need to know about MRD as it relates to their disease status and treatment. Finally, we discuss ongoing challenges and future directions with the goal of optimizing MRD usage in leukemia management.
Topics & Concepts
Myeloid leukemiaMedicineMinimal residual diseaseDiseaseOncologyClinical significanceIntensive care medicineLeukemiaDisease managementClinical decision makingInternal medicineParkinson's diseaseChronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia research